Premium
Phenotypic changes of T‐lymphocyte subsets induced by interleukin‐12 and interleukin‐15 in umbilical cord vs. adult peripheral blood mononuclear cells
Author(s) -
Lin SyhJae,
Chao HsunChin,
Yan DahChin
Publication year - 2001
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1034/j.1399-3038.2001.012001021.x
Subject(s) - peripheral blood mononuclear cell , il 2 receptor , cd3 , medicine , immunology , cd8 , umbilical cord , cord blood , cytokine , lymphocyte , immune system , t cell , biology , in vitro , biochemistry
The decreased incidence of graft‐vs.‐host disease found following umbilical cord blood (CB) transplantation, and the increased susceptibility of newborns to infections, have been attributed, in part, to functional and phenotypic immaturity of neonatal T cells. We investigated the phenotypic changes of CB T cells induced by two immunoregulary cytokines, interleukin (IL)‐12 and IL‐15, alone or in combination. Adult peripheral blood (APB) mononuclear cells (MNCs) were also tested for comparison. Prior to culture, the percentages of CD3 + CD8 + , CD3 + CD25 + , and CD3 + CD56 + cells were significantly lower in CB MNCs than in APB MNCs. IL‐15, but not IL‐12, significantly increased CD3 + CD8 + expression among the CB MNCs after 1 week of culture. Combining IL‐12 and IL‐15, however, resulted in decreased CB CD3 + CD8 + expression compared with IL‐15 alone. The percentage of CD3 + CD25 + cells in CB MNCs spontaneously increased in the absence of cytokines, while that of CD3 + CD56 + cells in CB MNCs could not be enhanced with cytokines. In contrast, the percentages of CD3 + CD25 + and CD3 + CD56 + cells among the APB MNCs could be increased with IL‐12, IL‐15, and further with IL‐12 and IL‐15 combined. Thus, different patterns of T‐cell subset changes were demonstrated between CB MNCs and APB MNCs in response to IL‐12 and/or IL‐15. These data may serve as a foundation for using cytokine therapy in newborns and children receiving CB transplants.